JP2019509349A5 - 神経膠腫処置用の医薬組成物 - Google Patents
神経膠腫処置用の医薬組成物 Download PDFInfo
- Publication number
- JP2019509349A5 JP2019509349A5 JP2019500734A JP2019500734A JP2019509349A5 JP 2019509349 A5 JP2019509349 A5 JP 2019509349A5 JP 2019500734 A JP2019500734 A JP 2019500734A JP 2019500734 A JP2019500734 A JP 2019500734A JP 2019509349 A5 JP2019509349 A5 JP 2019509349A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eflornithine
- composition according
- glioma
- vincristine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 20
- 206010018338 Glioma Diseases 0.000 title claims 11
- 229960002759 eflornithine Drugs 0.000 claims 13
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims 11
- 229960004528 Vincristine Drugs 0.000 claims 9
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 9
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 8
- 229960002247 lomustine Drugs 0.000 claims 6
- 229960004562 Carboplatin Drugs 0.000 claims 4
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 4
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 4
- 229960003433 Thalidomide Drugs 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 229960000624 procarbazine Drugs 0.000 claims 4
- 229960004964 temozolomide Drugs 0.000 claims 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 4
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- 229960001433 Erlotinib Drugs 0.000 claims 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- -1 chloretadine Chemical compound 0.000 claims 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 2
- 206010002224 Anaplastic astrocytoma Diseases 0.000 claims 2
- 102100003755 CCNO Human genes 0.000 claims 2
- 101700047412 CCNO Proteins 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 101700024037 IDH1 Proteins 0.000 claims 2
- 102100004121 IDH1 Human genes 0.000 claims 2
- 101700066748 IDH3B Proteins 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960001278 Teniposide Drugs 0.000 claims 2
- 229960005454 Thioguanine Drugs 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 201000011626 grade III astrocytoma Diseases 0.000 claims 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 2
- 229940027318 hydroxyurea Drugs 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-ADLMHZFOSA-N rapamycin Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-ADLMHZFOSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 claims 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims 1
- 102100002848 ATRX Human genes 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- AXRCEOKUDYDWLF-UHFFFAOYSA-N Enzastaurin Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 claims 1
- 229950002189 Enzastaurin Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 101700030371 IDH2 Proteins 0.000 claims 1
- 102100002772 IDH2 Human genes 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 241001135902 Peanut clump virus Species 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 229940104230 Thymidine Drugs 0.000 claims 1
- 229950009158 Tipifarnib Drugs 0.000 claims 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 Vorinostat Drugs 0.000 claims 1
- 108010069188 X-linked Nuclear Protein Proteins 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229950002389 diaziquone Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 claims 1
- 229950003662 fenretinide Drugs 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
Claims (15)
- （ａ）治療有効量のエフロルニチンまたはエフロルニチンの誘導体もしくは類似体、
（ｂ）場合によっては、エフロルニチンまたはエフロルニチンの誘導体もしくは類似体と一緒に投与できる治療有効量の少なくとも１種の追加的薬剤、および
（ｃ）医薬的に許容し得る担体
を含む、神経膠腫処置用の医薬組成物であって、
テモゾロミド再発性退形成性星細胞腫患者の神経膠腫の突然変異速度を低下させて前記神経膠腫の進行を低減化するために投与される、医薬組成物。 - 前記神経膠腫が、退形成性星細胞腫である、請求項１に記載の医薬組成物。
- 前記エフロルニチンまたはその誘導体もしくは類似体が、エフロルニチンである、請求項１に記載の医薬組成物。
- 前記エフロルニチンが、前記エフロルニチンの塩形態である、請求項３に記載の医薬組成物。
- 前記エフロルニチンが、Ｄ−エフロルニチンとＬ−エフロルニチンのラセミ混合物である、請求項３に記載の医薬組成物。
- 前記エフロルニチンが、Ｄ−エフロルニチンである、請求項３に記載の医薬組成物。
- 前記エフロルニチンが、Ｌ−エフロルニチンである、請求項３に記載の医薬組成物。
- 前記医薬組成物が経口投与される、請求項１に記載の医薬組成物。
- 前記神経膠腫が、ＩＤＨ１、ＩＤＨ２、ＴＰ５３、ＰＴＥＮおよびＡＴＲＸから成る群から選択される１種以上の遺伝子において突然変異を有する、請求項１に記載の医薬組成物。
- 前記神経膠腫が、ＩＤＨ１に突然変異を有する、請求項９に記載の医薬組成物。
- 前記神経膠腫が、ＲＢおよびＡＫＴ−ｍＴＯＲ経路に突然変異を有する、請求項１に記載の医薬組成物。
- 前記医薬組成物が、さらに神経膠腫の処置に使用される治療有効量の１種以上の抗新生物薬を含む、請求項１に記載の医薬組成物。
- 前記の神経膠腫の処置で使用される１種以上の抗新生物薬が、ロムスチン（ＣＣＮＵ）、カルムスチン（ＢＣＮＵ）、テモゾロミド、プロカルバジン、プレドニゾン、ビンクリスチン、ＰＣＶ（ロムスチン、プロカルバジンおよびビンクリスチンの組み合わせ）、カルボプラチン、カルボプラチン＋チミジン、カルムスチン＋テモゾロミド、エルロチニブ、カルボプラチン＋エルロチニブ、クロレタジン、ロムスチン＋クロレタジン、イマチニブ、ヒドロキシ尿素、ヒドロキシ尿素＋イマチニブ、イリノテカン、サリドマイド、テモゾロミド＋サリドマイド、リロツムマブ、シレンジタイド、シスレチノイン酸、セレコキシブ、シスレチノイン酸＋セレコキシブ、エンザスタウリン、シロリムス、エルロチニブ＋シロリムス、フェンレチニド、ゲフィチニブ、ラパチニブ、テムシロリムス、チピファルニブ、ボリノスタット、ジアジクオン、メトトレキサート、メルファラン、ビンクリスチンとプレドニゾンとプロカルバジンの組み合わせ、チオグアニン、ＴＰＤＣＶ（チオグアニン、プロカルバジン、ジブロモズルシトール、ロムスチン、ビンクリスチン）、窒素マスタードとビンクリスチンとプロカルバジンの組み合わせ、テノポシド、およびカルボプラチン＋テノポシドから成る群から選択される、請求項１２に記載の医薬組成物。
- 前記の神経膠腫の処置で使用される１種以上の抗新生物薬が、ロムスチン（ＣＣＮＵ）を含む、請求項１３に記載の医薬組成物。
- 前記医薬組成物が、さらにポリアミン輸送阻害剤を含む、請求項１に記載の医薬組成物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022066296A JP2022095882A (ja) | 2016-03-24 | 2022-04-13 | 神経膠腫を含むがんを処置するためのエフロルニチンおよびその誘導体および類似体の組成物ならびにそれらの使用方法 |
| JP2024083010A JP2024109766A (ja) | 2016-03-24 | 2024-05-22 | 医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312623P | 2016-03-24 | 2016-03-24 | |
| US62/312,623 | 2016-03-24 | ||
| PCT/US2017/022718 WO2017165187A1 (en) | 2016-03-24 | 2017-03-16 | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066296A Division JP2022095882A (ja) | 2016-03-24 | 2022-04-13 | 神経膠腫を含むがんを処置するためのエフロルニチンおよびその誘導体および類似体の組成物ならびにそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509349A JP2019509349A (ja) | 2019-04-04 |
| JP2019509349A5 true JP2019509349A5 (ja) | 2020-04-23 |
Family
ID=59896896
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500734A Pending JP2019509349A (ja) | 2016-03-24 | 2017-03-16 | 神経膠腫を含むがんを処置するためのエフロルニチンおよびその誘導体および類似体の組成物ならびにそれらの使用方法 |
| JP2022066296A Pending JP2022095882A (ja) | 2016-03-24 | 2022-04-13 | 神経膠腫を含むがんを処置するためのエフロルニチンおよびその誘導体および類似体の組成物ならびにそれらの使用方法 |
| JP2024083010A Pending JP2024109766A (ja) | 2016-03-24 | 2024-05-22 | 医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066296A Pending JP2022095882A (ja) | 2016-03-24 | 2022-04-13 | 神経膠腫を含むがんを処置するためのエフロルニチンおよびその誘導体および類似体の組成物ならびにそれらの使用方法 |
| JP2024083010A Pending JP2024109766A (ja) | 2016-03-24 | 2024-05-22 | 医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170273926A1 (ja) |
| EP (1) | EP3432872B1 (ja) |
| JP (3) | JP2019509349A (ja) |
| KR (2) | KR102452370B1 (ja) |
| CN (1) | CN109152758A (ja) |
| AU (2) | AU2017236646A1 (ja) |
| CA (1) | CA3018821C (ja) |
| DK (1) | DK3432872T3 (ja) |
| ES (1) | ES2896735T3 (ja) |
| IL (1) | IL261920A (ja) |
| MX (1) | MX2018011536A (ja) |
| PL (1) | PL3432872T3 (ja) |
| WO (1) | WO2017165187A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170273926A1 (en) * | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP3523274A4 (en) | 2016-10-06 | 2020-05-13 | Orbus Therapeutics, Inc. | FORMULATIONS FOR THE ADMINISTRATION OF EFLORNITHIN |
| JP7254780B2 (ja) | 2017-09-20 | 2023-04-10 | オクラホマ・メディカル・リサーチ・ファウンデーション | 薬剤耐性神経膠腫の治療法 |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| CN110646557A (zh) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途 |
| WO2023235504A2 (en) * | 2022-06-01 | 2023-12-07 | Syncromune, Inc. | A method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2083030B (en) * | 1980-08-23 | 1984-03-07 | Merrell Toraude & Co | Fluorinated pentene diamine derivatives |
| ES2193247T3 (es) | 1996-05-24 | 2003-11-01 | Jong Eduard Karel De | Sistema y metodo de proteccion criptografica de comunicaciones. |
| JP2000507613A (ja) | 1996-11-01 | 2000-06-20 | アイレックス・オンコロジー・インコーポレイテッド | Ｄｆｍｏ含有持続放出配合物 |
| US6646149B1 (en) * | 1997-07-15 | 2003-11-11 | Nicolaas M. J. Vermeulin | Polyamine analogues as therapeutic and diagnostic agents |
| US6949679B1 (en) * | 1998-04-21 | 2005-09-27 | Universite Laval | Polyamine transport inhibitors |
| BR9916518A (pt) * | 1998-12-23 | 2002-01-29 | Searle & Co | Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos |
| US20030203956A1 (en) | 1998-12-23 | 2003-10-30 | Masterrer Jaime L. | Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia |
| US6630511B2 (en) | 2000-08-01 | 2003-10-07 | Rolland F. Hebert | Water-soluble salts of 2-difluoromethyl-2,5-diaminopentanoic acid (DFMO) |
| WO2003015763A1 (en) * | 2001-08-13 | 2003-02-27 | Board Of Regents, The University Of Texas System | Adjuvant chemotherapy for anaplastic gliomas |
| SE0401871D0 (sv) | 2004-07-15 | 2004-07-15 | Glucogene Medical Hfm Ab | New compositions |
| US7655678B2 (en) | 2004-11-30 | 2010-02-02 | Council of Scientfic & Industrial Research | Pharmaceutical composition for the management of tumors |
| WO2007075673A1 (en) | 2005-12-20 | 2007-07-05 | University Of Hawaii | Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors |
| US8497398B1 (en) | 2007-05-02 | 2013-07-30 | University Of Central Florida Research Foundation, Inc. | Polyamine transporter selective compounds as anti-cancer agents |
| US8597904B2 (en) | 2007-11-14 | 2013-12-03 | Pono Corporation | Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition |
| CN102177251B (zh) * | 2008-09-03 | 2017-06-16 | 约翰·霍普金斯大学 | 恶性神经胶质瘤的异柠檬酸脱氢酶和其他基因的遗传改变 |
| US20100120727A1 (en) * | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
| US20130209450A1 (en) * | 2010-01-05 | 2013-08-15 | Yael Cohen | Compositions and Methods for Treating Glioblastoma GBM |
| WO2011113005A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| US20110256161A1 (en) | 2010-04-19 | 2011-10-20 | Aminex Therapeutics Inc. | Methods for enhancing immune response |
| US9901563B2 (en) * | 2013-03-11 | 2018-02-27 | Delmar Pharmaceuticals, Inc. | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
| EP2830603B1 (en) | 2012-03-28 | 2018-09-26 | University of Central Florida Research Foundation, Inc. | Polyamine transport selective therapeutic agents with enhanced stability |
| WO2014085579A1 (en) * | 2012-11-30 | 2014-06-05 | Northeastern University | Copolymers for the delivery of drugs into cells |
| US20170273926A1 (en) * | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
-
2016
- 2016-07-25 US US15/218,149 patent/US20170273926A1/en not_active Abandoned
-
2017
- 2017-03-16 PL PL17770846T patent/PL3432872T3/pl unknown
- 2017-03-16 KR KR1020187030685A patent/KR102452370B1/ko active IP Right Grant
- 2017-03-16 AU AU2017236646A patent/AU2017236646A1/en not_active Abandoned
- 2017-03-16 EP EP17770846.8A patent/EP3432872B1/en active Active
- 2017-03-16 DK DK17770846.8T patent/DK3432872T3/da active
- 2017-03-16 MX MX2018011536A patent/MX2018011536A/es unknown
- 2017-03-16 WO PCT/US2017/022718 patent/WO2017165187A1/en active Application Filing
- 2017-03-16 JP JP2019500734A patent/JP2019509349A/ja active Pending
- 2017-03-16 CN CN201780028645.8A patent/CN109152758A/zh active Pending
- 2017-03-16 ES ES17770846T patent/ES2896735T3/es active Active
- 2017-03-16 US US16/087,195 patent/US20190091187A1/en not_active Abandoned
- 2017-03-16 KR KR1020227034401A patent/KR20220140027A/ko active Application Filing
- 2017-03-16 CA CA3018821A patent/CA3018821C/en active Active
-
2018
- 2018-09-23 IL IL261920A patent/IL261920A/en unknown
-
2022
- 2022-04-13 JP JP2022066296A patent/JP2022095882A/ja active Pending
-
2023
- 2023-02-02 AU AU2023200537A patent/AU2023200537A1/en active Pending
-
2024
- 2024-05-22 JP JP2024083010A patent/JP2024109766A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509349A5 (ja) | 神経膠腫処置用の医薬組成物 | |
| JP2017527532A5 (ja) | ||
| JP2014500295A5 (ja) | ||
| JP2019502763A5 (ja) | ||
| JP2017510610A5 (ja) | ||
| JP2011505347A5 (ja) | ||
| JP2019510832A5 (ja) | ||
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| JP2016535795A5 (ja) | ||
| JP2014526503A5 (ja) | ||
| JP2015512406A5 (ja) | ||
| JP2017520607A5 (ja) | ||
| JP2015038149A5 (ja) | ||
| JP2017519781A5 (ja) | ||
| JP2020536919A5 (ja) | ||
| JP2013507415A5 (ja) | ||
| JP2016525102A5 (ja) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2012502017A5 (ja) | ||
| JP2022095882A5 (ja) | 医薬組成物 | |
| JP2014114295A5 (ja) | ||
| JP2017502092A5 (ja) | ||
| IL273169B1 (en) | A new combination of active substances for the treatment of advanced lymphoid interstitial lung diseases | |
| JP2015535247A5 (ja) |